American society of clinical oncology policy statement: The role of the oncologist in cancer prevention and risk assessment

Journal of Clinical Oncology

Volumn 27, Issue 6, 2009, Pages 986-993

  Zon, Robin T ^a   Goss, Elizabeth ^a   Vogel, Victor G ^a   Chlebowski, Rowan T ^a   Jatoi, Ismail ^a   Robson, Mark E ^a   Wollins, Dana S ^a   Garber, Judy E ^a   Brown, Powel ^a   Kramer, Barnett S ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; CALCIUM; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; FINASTERIDE; HEPATITIS B VACCINE; NONSTEROID ANTIINFLAMMATORY AGENT; RALOXIFENE; RETINOID; TAMOXIFEN; WART VIRUS VACCINE;

BEHAVIOR CHANGE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CANCER SURGERY; CANCER SURVIVOR; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; COLORECTAL CANCER; FAMILIAL CANCER; HEAD AND NECK CANCER; HEALTH CARE ACCESS; HEALTH EDUCATION; LIVER CANCER; MEDICAL PRACTICE; MEDICAL SOCIETY; MEDICAL SPECIALIST; NEOPLASM; PATIENT COUNSELING; PATIENT EDUCATION; PHYSICIAN; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; SMOKING CESSATION; TOBACCO; UTERINE CERVIX CANCER;

GENETIC PREDISPOSITION TO DISEASE; HEALTH BEHAVIOR; HUMANS; INTERDISCIPLINARY COMMUNICATION; MEDICAL ONCOLOGY; NEOPLASMS; PHYSICIAN'S ROLE; PRIMARY HEALTH CARE; RISK ASSESSMENT;

EID: 60949092435     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.3691     Document Type: Review

References (81)

1. ASCO: 2004-2007 ASCO Strategic Plan to Improve Cancer Careand Prevention. http://www.asco.org/asco/downloads/ASCO-Strategic-Plan-2004-2007.pdf
2. Ganz PA, Kwan L, Somerfield M, et al: The role of prevention in oncology practice: Results from a 2004 survey of American Society of Clinical Oncology members. J Clin Oncol 24:2948-2957, 2006
3. Chlebowski RT, Sayre J, Frank-Stromborg M, et al: Current attitudes and practice of American Society of Clinical Oncology-member clinical oncologists regarding cancer prevention and control. J Clin Oncol 10:164-168, 1992
4. American Cancer Society. Cancer Facts & Figures 2005. www.cancer.org
5. Centers for Disease Control and Prevention: Tobacco-Related Mortality. www.cdc.gov/tobacco/factsheets/Tobacco-Related-Mortality-factsheet.htm
6. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute: Smoking Cessation and Continued Risk in Cancer Patients. January 23, 2003, http://www.nci.nih.gov/cancerinfo/pdq/ supportivecare/smokingcessation/healthprofessional
7. Browman GP, Wong G, Hodson I, et al: Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med 328:159-163, 1993
8. Do KA, Johnson MM, Doherty DA, et al: Second primary tumors in patients with upper aero-digestive tract cancers: Joint effects of smoking and alcohol. Cancer Causes Control 14:131-138, 2003
9. Substance Abuse and Mental Health Services Administration (2005): Results from the 2005 National Survey on Drug Use and Health. (PDF-1.41MB) (Office of Applied Studies, NSDUH Series H-27, DHHS Publication No. SMA 05-4061) Rock-ville, MD. http://oas.samhsa.gov/nsduh/2k5nsduh/2k5results.pdf
10. Gritz ER, Fingeret MC, Vidrine DF, et al: Successes and failures of the teachable moment: Smoking cessation in cancer patients. Cancer 106: 17-27, 2006
11. Ore MC, Bailey WC, Cohen SJ, et al: U.S. Department of Health and Human Services: Treating tobacco use and dependence: Clinical practice guideline. Rockville, MD, Public Health Service, 2000
12. Centers for Medicare and Medicaid Services: National Coverage Determination for Smoking and Tobacco-Use Cessation Counseling (210.4). http://www.cms.hhs.gov/mcd
13. Claims data from CMS, 2006. Centers for Medicare and Medicaid Services: 2006 Physician/
14. Supplier Procedure Summary Master File. http://www.cms.hhs.gov/ NonIdentifiableDataFiles/06-PhysicianSupplierProcedureSummaryMasterFile.asp
15. Pfister D, Halpern AC: Skin squamous cell cancer: The time is right for greater involvement of the medical oncologist. J Clin Oncol 25:1953-1954, 2007
16. Vainio H, Bianchini F (eds): Weight Control and Physical Activity: IARC Handbooks of Cancer Prevention. Lyon, France, International Agency for Research on Cancer, 2002
17. Chlebowski RT, Blackburn G, Thomson CA, et al: Dietary fat reduction and breast cancer outcome: Interim efficacy results from the Women's Intervention Nutrition Study (WINS). J Natl Cancer Inst 98:1767-1776, 2006
18. Prentice RL, Cann B, Chlebowski RT, et al: Women's Health Initiative trial of a low- fat dietary pattern and breast cancer. JAMA 295:629-642, 2006
19. Pierce JP, Stefanick ML, Flatt SW, et al: Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol 25:2345-2351, 2007
20. McTiernan A (ed): Cancer Prevention and Management Through Exercise and Weight Control. New York, NY, Taylor and Francis CRC Press, 2005
21. Friedenreich CM, Orenstein MR: Physical activity and cancer prevention: Etiologic evidence and biological mechanisms. J Nutr 132:3456-3464,2002 (suppl 11)
22. Courneya KS: Exercise in cancer survivors: An overview of research. Med Sci Sports Exerc 35:1846-1852, 2003
23. Galvao DA, Newton RU: Review of exercise intervention studies in cancer patients. J Clin Oncol 23:899-909, 2005
24. Demark-Wehnefried W, Azi NM, Rowland JH, et al: Riding the crest of the teachable moment: Promoting long-term health after the diagnosis of cancer. J Clin Oncol 23:5814-5830, 2005
25. Oeffinger KC, Mertens AC, Sklar CA, et al: Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572-1582, 2006
26. Ganz PA: A teachable moment for oncologists: Cancer survivors, 10 million strong and growing! J Clin Oncol 23:5458-5460, 2005
27. Knols R, Aaronson NK, Uebelhart D, et al: Physical exercise in cancer patients during and after medical treatment: A systematic review of randomized and controlled clinical trials. J Clin Oncol 23:3830-3842, 2005
28. Demark-Wahnefried W, Pinto BM, Gritz ER: Promoting health and physical function among cancer survivors: Potential for prevention and questions that remain. J Clin Oncol 24:5125-5131, 2006
29. ASCO: ChemotherapyTreatment. http://www.asco.org/treatmentsummary
30. Hewitt ME, Simone JV: Ensuring Quality Cancer Care. Washington, DC, Institute of Medicine Committee, National Cancer Policy Board, 1999
31. Gail MH, Brinton LA, Bryar DP, et al: Protecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879-1886, 1989
32. Bondy ML, Newman LA: Assessing breast cancer risk: Evolution of the Gail Model. J Natl Cancer Inst 98:1 172-1173, 2006
33. Chen J, Pee D, Ayyagari R, et al: Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 98:1125-1226, 2006
34. Barlow WE, White E, Ballard-Barbash R, et al: Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 98:1204-1214, 2006
35. Elmore JG, Fletcher SW: The risk of cancer risk prediction: "What is my risk of getting breast cancer?" J Natl Cancer Inst 98:1673-1675, 2006
36. Decarli A, Calza S, Masala G, et al: Gail Model for prediction of absolute risk of invasive breast cancer: Independent evolution in the Florence-European prospective investigation into cancer and nutrition cohort. J Natl Cancer Inst 98:1686-1693, 2006
37. New NCI Risk Website Aims at Consumers. J Natl Cancer Inst 98:1596-1598, 2006
38. Harvard: School of Public Health: Your disease risk. http://www. yourdiseaserisk.harvard.edu
39. Central Pennsylvania Medical Oncology Group: Cancer risk assessment. http://www.hmc.psu.edu/cpog/risk/index.htm
40. Fox Chase Cancer Center: What are your cancer risks? www.fccc.edu/cancer/ risk-quiz.html
41. Mayo Clinic http://www.mayoclinic.com/health/ cancer-prevention/CA00024
42. Garber JE, Offit K: Hereditary cancer predisposition syndromes. J Clin Oncol 23:276-292, 2005
43. Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. J Clin Oncol 14:1730-1736, 1996
44. American Society of Clinical Oncology: Policy Statement Update: Genetic Testing for Cancer Susceptibility. J Clin Oncol 21:2397-2406, 2003
45. Zon R, Ndoping M, Colbert A, et al: Reimbursement for preventive counseling services. J Oncol Pract 2:214-218, 2006
46. Ganz P, Kwan L, Somerfield M, et al: The Role of prevention in oncology practice: Results from a 2004 survey of American Society of Clinical Oncology members. J Clin Oncol 24:2498-2957, 2006
47. Hartmann LC, Schaid DJ, Woods JE, et al: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77-84, 1999
48. Meijers-Jeijboer H, van Geel B, van Putten WL, et al: Breast cancer after prophylactic bilateral mastectomy in women with a BRCA 1 or BRCA 2 mutation. N Engl J Med 345:159-164, 2001
49. Rebbeck TR, Friebel T, Lynch HT, et al: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA 1 and BRCA 2 mutation carriers: The PROSE Study Group. J Clin Oncol 22:1055-1062, 2004
50. Rebbeck TR, Lynch HT, Neuhausen SL, et al: Prophylactic oophorectomy in carriers of BRCA 1 or BRCA 2 mutations. N Engl J Med 346:1616-1622, 2002
51. Kriege M, Brekelmans CTM, Boetes C, et al: Efficacy of MRI, and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427-437, 2004
52. Narod SA, Brunet JS, Ghadrian P, et al: Hereditary Breast Cancer Clinical Study Group: Tamox-ifen and risk of contralateral breast cancer in BRCA 1 and BRCA 2 mutation carriers: A case control study. Lancet 356:1876-1881, 2000
53. Guillem JG, Wood WC, Moley JF, et al: ASCO/SSO Review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 24:4642-4660, 2006
54. Lakhani VT, You YN, Wells SA: The multiple endocrine neoplasia syndromes. Annu Rev Med 58:253-265, 2007
55. Gail MH, Costantino JP, Bryant J, et al: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91:1829-1846, 1999
56. Fisher B, Constantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1988
57. Vogel VG, Costantino JP, Wickerham DL, et al: Effects of tamoxifen: Raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727-2741, 2006
58. Lucia MS: Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99:1375-1383, 2007
59. Cohen YC: Detection bias due to the effect of finasteride on prostate volume: A modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99:1366-1374, 2007
60. Thompson IM, Goodman PJ, Tangen CM, et al: The influence of finasteride on the development of prostate cancer. N Engl J Med 349:211-220, 2003
61. Thompson IM, Klein EA, Lippman SM, et al: Prevention of prostate cancer with finasteride: US/ European perspective. Eur Urol 44:650-655, 2003
62. Wactawski-Wende J, Kotchen JM, Anderson G, et al: Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 354:684-696, 2006
63. Hawk ET, Limburg PJ, Viner JL: Epidemiology and prevention of colorectal cancer. Surg Clin North Am 82:905-941, 2002
64. Grau MV, Rees JR, Baron JA: Chemopreven-tion in gastrointestinal cancers: Current status. Basic& Clinical Pharmacology & Toxicology 98:281-287, 2006
65. Chlebowski RT, Wactawski-Wende JM, Hubbell A, et al: Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350:991-1004, 2004
66. Chiesa F, Tradati N, Marazza M, et al: Fen-retinide (4-HPR) in chemoprevention of oral leuko-plakia. J Cell Biochem 17F:255-261, 1993 (suppl)
67. Hong WK, Lippman SM, Itri LM, et al: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323:795-801, 1990
68. Lippman SM, Batsakis JG, Toth BB, et al: Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 328:15-20, 1994
69. Papadimitrakopoulou VA, Clayman GL, Shin DM, et al: Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolar- yngol Head Neck Surg 125:1083-1089, 1999
70. Seixas-Silva JA Jr, Richards TA, Khuri FR, et al: Phase II bioadjuvant study of interferon-alpha, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: Long-term follow-up. Arch Otolaryngol Head and Neck Surg 131:304-307, 2005
71. Koehne CH, Dubois RN: COX inhibition and colorectal cancer. Semin Oncol 31:12-21, 2004
72. Reckamp KL, Dubinett SM, Krysan K, et al: A phase I trial of targeted COX-2 and EGRF TK inhibition in advanced NSCLC. J Clin Oncol 41, 2005 (abstr 7112)
73. Wirth LJ, Haddad RI, Lindeman NI, et al: Phase I study of gefitinib plus celexob in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 23:6976-6981, 2005
74. Zhang X, Chen Z, Choe MS, et al: Tumor growth inhibition by simultaneously blocking EGFR and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 1 1:6261-6269, 2005
75. Chang MH, Chen CJ, Lai MS, et al: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 336:1855-1859, 1997
76. Wands JR: Prevention of hepatocellular carcinoma. N Engl J Med 351:1567-1570, 2004
77. Koutsky LA, Ault KA, Wheeler CM, et al: A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347:1645-1651, 202
78. Villa LL, Cost RL, Petta CA, et al: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271-278, 2005
79. Ganz PA, Kwan L, Somerfield MR, et al: The role of prevention in oncology practice: Results from a 2004 survey of American Society of Clinical Oncology members. J Clin Oncol 24:2948-2957, 2006
80. Insurer Policies on Preventive Counseling by Medical Oncologists, Prepared by Avalere Health LLC for American Society of Clinical Oncology, February 6, 2006
81. Zon R, Towle E, Ndoping M, et al: Reimbursement for prevention counseling services. J Oncol Pract 2:214-218, 2006